Madrigal Pharmaceuticals, Inc. (FRA:YDO1)
494.20
-10.60 (-2.10%)
At close: Dec 5, 2025
Madrigal Pharmaceuticals Revenue
Madrigal Pharmaceuticals had revenue of $287.27M USD in the quarter ending September 30, 2025, with 362.03% growth. This brings the company's revenue in the last twelve months to $740.64M, up 864.21% year-over-year. In the year 2024, Madrigal Pharmaceuticals had annual revenue of $180.13M.
Revenue (ttm)
$740.64M
Revenue Growth
+864.21%
P/S Ratio
17.85
Revenue / Employee
$1.40M
Employees
528
Market Cap
11.27B EUR
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Madrigal Pharmaceuticals News
- 1 day ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Madrigal Pharmaceuticals (MDGL) Sees Analyst Upgrade with Target Price Raised to $620 | MDGL ... - GuruFocus
- 15 days ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 15 days ago - Madrigal Pharmaceuticals (MDGL): Oppenheimer Raises Price Target to $650 | MDGL Stock News - GuruFocus
- 16 days ago - Madrigal Pharmaceuticals (MDGL) Rating Maintained and Price Target Raised by Truist Securities ... - GuruFocus
- 18 days ago - Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Madrigal Pharmaceuticals (MDGL): Analyst Maintains Buy Rating, Raises Price Target | MDGL Stock News - GuruFocus